Abbasinazari Mohammad, Adib-Eshgh Ladan, Rostami Azin, Beyraghi Narges, Dabir Shideh, Jafari Reyhaneh
Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Asian J Psychiatr. 2015 Jun;15:5-9. doi: 10.1016/j.ajp.2015.04.002. Epub 2015 Apr 22.
The purpose of this study was to evaluate the effect of memantine administration on the adverse cognitive effects of electroconvulsive therapy (ECT). Forty patients diagnosed with a major depressive disorder for which ECT was indicated as a treatment for their current episode were randomly allocated to either the memantine (5mg/day) group or the placebo group. All patients underwent the same protocol for anaesthesia and ECT procedures. The patients received memantine or the placebo for the whole period of ECT treatment, starting the day before ECT and continuing until the fourth session of ECT. The Modified Mental State Examination (MMSE) was used for the assessment of cognition before and after the trial. Regarding MMSE and item 3 MMSE (related to recent memory), the memantine group scored significantly higher at the end of ECT sessions than the control group (P=0.02, P<0.001, respectively). Our data support the hypothesis that memantine may reduce cognitive impairment following ECT. Memantine could be both a safe and well-tolerated treatment for use with ECT.
本研究的目的是评估美金刚给药对电休克治疗（ECT）不良认知效应的影响。40例被诊断为重度抑郁症且当前发作期需ECT治疗的患者被随机分配至美金刚（5mg/天）组或安慰剂组。所有患者接受相同的麻醉和ECT程序方案。患者在整个ECT治疗期间接受美金刚或安慰剂，从ECT前一天开始，持续至ECT第四疗程。采用改良精神状态检查（MMSE）评估试验前后的认知情况。关于MMSE及MMSE第3项（与近期记忆有关），美金刚组在ECT疗程结束时的得分显著高于对照组（分别为P = 0.02，P < 0.001）。我们的数据支持美金刚可能减轻ECT后认知损害的假说。美金刚可能是一种与ECT联合使用安全且耐受性良好的治疗方法。
